BRISTOL-MYERS SQUIBB COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $8.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $8.00M, a 38.46% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $13.00M, a 85.56% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $90.00M, a 82.89% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $526.00M, a 2.73% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $8.00M 10-K · filed 2026-02-11 |
| 2024-12-31 | $13.00M 10-K · filed 2026-02-11 |
| 2023-12-31 | $90.00M 10-K · filed 2026-02-11 |
| 2022-12-31 | $526.00M 10-K · filed 2025-02-12 |
| 2021-12-31 | $512.00M 10-K · filed 2024-02-13 |
| 2020-12-31 | $556.00M 10-K · filed 2023-02-14 |
| 2019-12-31 | $148.00M 10-K · filed 2022-02-09 |
| 2018-12-31 | $89.00M 10-K · filed 2021-02-10 |
| 2017-12-31 | $84.00M 10-K · filed 2020-02-24 |
| 2016-12-31 | $158.00M 10-K · filed 2019-02-25 |
| 2015-12-31 | $206.00M 10-K · filed 2018-02-13 |
| 2014-12-31 | $199.00M 10-K · filed 2017-02-21 |
| 2013-12-31 | $323.00M 10-K · filed 2016-02-12 |
| 2012-12-31 | $153.00M 10-K · filed 2015-02-13 |
| 2011-12-31 | $154.00M 10-K · filed 2014-02-14 |
| 2010-12-31 | $47.00M 10-K · filed 2013-02-15 |
| 2009-12-31 | $6.00M 10-K · filed 2012-02-17 |
| 2008-12-31 | $2.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |